Back to Search
Start Over
Regulating RISK: a role for JAK-STAT signaling in postconditioning?
- Source :
-
American journal of physiology. Heart and circulatory physiology [Am J Physiol Heart Circ Physiol] 2008 Oct; Vol. 295 (4), pp. H1649-56. Date of Electronic Publication: 2008 Aug 15. - Publication Year :
- 2008
-
Abstract
- Postconditioning (POC), a novel strategy of cardioprotection against ischemia-reperfusion injury, is clinically attractive because of its therapeutic application at the predictable onset of reperfusion. POC activates several intracellular kinase signaling pathways, including phosphatidylinositol 3-kinase (PI3K)-Akt (RISK). The regulation of POC-induced survival kinase signaling, however, has not been fully characterized. JAK-STAT activation is integral to cardiac ischemic tolerance and may provide upstream regulation of RISK. We hypothesized that POC requires the activation of both JAK-STAT and RISK signaling. Langendorff-perfused mouse hearts were subjected to 30 min of global ischemia and 40 min of reperfusion, with or without POC immediately after ischemia. A separate group of POC hearts was treated with AG 490, a JAK2 inhibitor, Stattic, a specific STAT3 inhibitor, or LY-294002, a PI3K inhibitor, at the onset of reperfusion. Cardiomyocyte-specific STAT3 knockout (KO) hearts were also subjected to non-POC or POC protocols. Myocardial performance (+dP/dt(max), mmHg/s) was assessed throughout each perfusion protocol. Phosphorylated (p-) STAT3 and Akt expression was analyzed by Western immunoblotting. POC enhanced myocardial functional recovery and increased expression of p-STAT3 and p-Akt. JAK-STAT inhibition abrogated POC-induced functional protection. STAT3 inhibition decreased expression of both p-STAT3 and p-Akt. PI3K inhibition also attenuated POC-induced cardioprotection and reduced p-Akt expression but had no effect on STAT3 phosphorylation. Interestingly, STAT3 KO hearts undergoing POC exhibited improved ischemic tolerance compared with KO non-POC hearts. POC induces myocardial functional protection by activating the RISK pathway. JAK-STAT signaling, however, is insufficient for effective POC without PI3K-Akt activation.
- Subjects :
- Animals
Chromones pharmacology
Cyclic S-Oxides pharmacology
Janus Kinases antagonists & inhibitors
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Morpholines pharmacology
Myocardial Contraction
Myocardial Reperfusion Injury enzymology
Myocardial Reperfusion Injury physiopathology
Myocytes, Cardiac drug effects
Phosphoinositide-3 Kinase Inhibitors
Phosphorylation
Protein Kinase Inhibitors pharmacology
Recovery of Function
STAT3 Transcription Factor antagonists & inhibitors
STAT3 Transcription Factor deficiency
STAT3 Transcription Factor genetics
Time Factors
Tyrphostins pharmacology
Ventricular Function, Left
Janus Kinases metabolism
Myocardial Reperfusion Injury prevention & control
Myocytes, Cardiac enzymology
Phosphatidylinositol 3-Kinases metabolism
Proto-Oncogene Proteins c-akt metabolism
STAT3 Transcription Factor metabolism
Signal Transduction drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 0363-6135
- Volume :
- 295
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- American journal of physiology. Heart and circulatory physiology
- Publication Type :
- Academic Journal
- Accession number :
- 18708442
- Full Text :
- https://doi.org/10.1152/ajpheart.00692.2008